Search results for "High-density lipoprotein cholesterol"

showing 5 items of 5 documents

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and …

2011

OBJECTIVE: To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL-C in high-risk patients treated with lipid-lowering therapy. DESIGN AND METHODS: This post-hoc analysis calculated LDL-C and non-HDL-C levels corresponding to an Apo B of 0.9 g/L following treatment with 1) statin monotherapy (baseline) and 2) ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg (study end). The percentages of patients reaching LDL-C, non-HDL-C, and Apo B targets were calculated at study end. RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goa…

MaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinApolipoprotein Bmedicine.drug_classHypercholesterolemiaClinical BiochemistryCoronary DiseaseGastroenterologyRosuvastatinEzetimibeEzetimibe/simvastatin; Rosuvastatin; Correlation; Apolipoprotein B; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterolInternal medicinemedicineHumansLow-density lipoprotein cholesterolRosuvastatinRosuvastatin CalciumAgedApolipoproteins BLdl cholesterolSulfonamidesbiologyEzetimibe/simvastatinbusiness.industrynutritional and metabolic diseasesGeneral MedicineMiddle AgedEzetimibeCorrelationFluorobenzenesNon-high-density lipoprotein cholesterolCholesterolPyrimidinesSimvastatinNon hdl cholesterolbiology.proteinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein Bmedicine.drugClinical Biochemistry
researchProduct

Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: insights from Italian general practice

2018

Background and aims: Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. Methods: Patients aged ≥18 years with a valid low-density lipoprotein cholesterol (LDL-C) measurement in 2015 were selected from the IMS Health Real World Data database; non-high-density lipoprotein cholesterol (non-HDL-C) was assessed in those with available total cholesterol measurements. Index dates were defined as the last valid lipid measurement in 2015. Patients were hierarchically classified into mutually exclusive risk categories: heterozygous familial hypercholesterolemia (primary and secondary prevention), atheroscler…

MaleTime FactorsSettore MED/09 - Medicina InternaDatabases FactualGeneral PracticeFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematology0302 clinical medicineRisk FactorsCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; StatinMedicine030212 general & internal medicinePractice Patterns Physicians'StrokeAged 80 and overLipid MeasurementMiddle AgedCardiovascular diseaseNon-high-density lipoprotein cholesterolCholesterolTreatment OutcomeItalyCardiovascular DiseasesCohortPractice Guidelines as Topiclipids (amino acids peptides and proteins)FemaleGuideline AdherenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeStatinCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; Statin; Cardiology and Cardiovascular Medicinemedicine.drug_classRisk Assessment03 medical and health sciencesDiabetes mellitusInternal medicineHumansLow-density lipoprotein cholesterolAgedDyslipidemiasRetrospective Studiesbusiness.industryPreventionStatinCholesterol LDLmedicine.diseaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkers
researchProduct

How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL

2017

Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cholesterol (LDL-C) through a statin therapy is a gold standard in the management of patients with dyslipidaemia and cardiovascular disease (CVD). However, even when LDL-C levels are at or below clinically recommended target levels, residual cardiovascular (CV) risk still remains. Therefore, assessing lipoproteins beyond LDL-C in managing CV risk is imperative. Methods: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a nu…

medicine.medical_specialtyApolipoprotein BType 2 diabetes030204 cardiovascular system & hematologyRisk AssessmentTriglyceride03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoprotein cholesterolRisk FactorsInternal medicinemedicineInternal MedicineHumans030212 general & internal medicineAtherogenic dyslipidaemiaHypolipidemic AgentsbiologyCholesterolbusiness.industryDisease Managementnutritional and metabolic diseasesGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCardiovascular diseaseCardiovascular riskResidual riskNon-high-density lipoprotein cholesterolEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessmentCardiology and Cardiovascular MedicineApolipoprotein BBiomarkersLipoproteinLipoprotein(a)
researchProduct

Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management

2013

Abstract Introduction and objectives Although atherogenic dyslipidemia is a recognized cardiovascular risk factor, it is often underassessed and thus undertreated and poorly controlled in clinical practice. The objective of this study was to reach a multidisciplinary consensus for the establishment of a set of clinical recommendations on atherogenic dyslipidemia to optimize its prevention, early detection, diagnostic evaluation, therapeutic approach, and follow-up. Methods After a review of the scientific evidence, a scientific committee formulated 87 recommendations related to atherogenic dyslipidemia, which were grouped into 5 subject areas: general concepts (10 items), impact and epidemi…

medicine.medical_specialtyConsensusDelphi TechniqueGuidelines as TopicScientific evidenceTherapeutic approachRisk FactorsMultidisciplinary approachEpidemiologymedicineHumansRisk factorDyslipidemiascomputer.programming_languageAtherogenic dyslipidemiaEvidence-Based Medicinebusiness.industryExpert consensusGeneral MedicineAtherosclerosisAtherogenic dyslipidemia Cardiovascular risk Consenso Consensus Delphi Dislipemia aterogénica HDL-C LDL-C Riesgo cardiovascular high-density lipoprotein cholesterol low-density lipoprotein cholesterolCardiovascular DiseasesFamily medicinePhysical therapybusinesscomputerDelphiRevista Española de Cardiología (English Edition)
researchProduct